Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine

Journal of Infectious Diseases

Volumn 175, Issue 6, 1997, Pages 1502-1506

  Imrie, Allison ^b   Beveridge, Alexander ^b   Genn, William ^b   Vizzard, Jeanette ^b   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG RESISTANCE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS TRANSMISSION;

EID: 0030953711     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516487     Document Type: Article

References (15)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989;243:1731-4.
2. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246: 1155-8.
3. Kellam P, Boucher CAB, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
4. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Los Alamos, NM: Los Alamos National Laboratories Database, 1994.
5. Richman DD, Havlir D, Corbeil B, et al. Nevirapine resistance mutations of HIV-1 selected during therapy. J Virol 1994;68:1660-6.
6. Imrie A, Carr A, Duncombe C, et al. Primary infection with zidovudine-resistant HIV-1 does not adversely affect outcome at 1 year. J Infect Dis 1996;174:195-8.
7. De Jong M, Lowenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1 - infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169:1346-50.
8. Schuittemaker H, Koot M, Koostra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocy-totropic to T-cell-tropic virus populations. J Virol 1992;66:1354-60.
9. De Jong MD, Schuurman R, Lange JMA, Boucher CAB. Rapid selective outgrowth of a minor pre-existing drug resistant HIV-1 subpopulation during subsequent nevirapine treatment [abstract]. In: Proceedings of the Fourth International HIV Drug Resistance Workshop, Sardinia, Italy, 6-9 July 1995.
10. Albert J, Wahlberg J, Lundeberg J, et al. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. J Virol 1992;66:5627-30.
11. Kinloch-De-Loes S, Hirschel B, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
12. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993;328:1163-5.
13. Centers for Disease Control and Prevention. Case control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 1995;44: 929-33.
14. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multi-drug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1993;42(RR-7).
15. Sonnerberg A, Johansson B, Ayehunie S, Julander I. Transmission of zidovudine-resistant HIV-1. AIDS 1993;7:1684-5.